Experiencia con el uso de toxina botulínica en niños con vejiga hiperactiva neurogénica: Una serie de casos

Resumen

Objetivo Describir la experiencia con la administración de inyección de toxina botulínica en niños con vejiga hiperactiva neurogénica refractaria a manejo de primera línea.

Materiales y Métodos Estudio observacional descriptivo (serie de casos) que incluyó a 14 niños con diagnóstico de vejiga hiperactiva neurogénica refractarios a tratamiento de primera línea sometidos a administración intravesical de toxina botulínica entre 2015 y 2021; se realizó el seguimiento teniendo en cuenta las variables clínicas, con evaluación de la respuesta y de los eventos adversos. Se reportaron frecuencias absolutas y porcentajes para las variables cualitativas; para las variables cuantitativas, se reportaron medidas de tendencia central y dispersión.

Resultados Se incluyeron 6 niños y 8 niñas, con una media de edad 10,1 (desviación estándar [DE]: ± 4,4) años. Todos los pacientes fueron tratados previamente con anticolinérgico y cateterismos limpios intermitentes, con una media de uso de 2,8 (DE: ± 1.0) pañales al día; 11 (78,5%) pacientes tenían antecedente de infección urinaria, 13 (92,8%), estreñimiento, y 2 (15,3%), incontinencia fecal. En la ecografía, 7 (50,0%) pacientes presentaban engrosamiento de las paredes vesicales, y 6 (42,8%), hidronefrosis. Tras el procedimiento, 1 paciente presentó infección urinaria como complicación, 6 presentaron una respuesta completa, 7, respuesta parcial, y 1 paciente no obtuvo respuesta con la primera inyección, con un tiempo promedio efectivo de la terapia 8 (DE: ± 6,3) meses. Una segunda inyección fue necesaria en 6 (42.8%) pacientes, y, de estos, 3 (50%) requirieron una tercera inyección.

Conclusión La inyección de toxina botulinica intravesical como terapia de segunda línea de manejo para vejiga hiperactiva neurogénica tiene buenos resultados, con bajas tasas de complicaciones.

Abstract

Objective To describe the experience with the administration of botulinum toxin injection in children with neurogenic overactive bladder who were refractory to the first-line management.

Materials and Methods A descriptive observational study (case series) which included 14 children with a diagnosis of neurogenic overactive bladder who were refractory to the first-line treatment and were aubmitted to the intravesical administration of botulinum toxin between 2015 and 2021. Follow-up was performed taking into account the clinical variables, wth an evaluation of the response and the adverse events. Absolute frequencies and percentages were reported for the qualitative variables; for the quantitative variables, measures of central tendency and dispersion were reported.

Results We included 6 boys and 8 girls with a mean age of 10.1 (standard deviation [SD]: ± 4.4) years. All patients were previously treated with anticholinergics and clean intermittent catheterizations, with a mean use of 2.8 (SD: ± 1.0) diapers per day; 11 (78.5%) had a history of urinary tract infection, 13 (92.8%), constipation, and 2 (15.3%), fecal incontinence. On ultrasound, 7 (50.0%) patients presented bladder wall thickening, and 6 (42.8%), hydronephrosis. After the procedure, 1 patient presented urinary tract infection as a complication, 6 presented complete response, 7, partial response, and 1 patient did not obtain a response with the first injection, with an effective mean time of therapy of 8 (SD: ± 6.3) months. A second injection was required by 6 (42.8%) patients, and of these, 3 (50%) required a third injection.

Conclusion Intravesical botulinum toxin injection as a second-line management therapy for neurogenic overactive bladder yileds good results, with low rates of complications.

Palabras Clave

detrusor hiperactivo neruogénico - toxina botulínica tipo A - niños - vejiga - incontinencia urinaria - mielomeningocele

Keywords

neurogenic detrusor overactivity - botulinum toxin type A - children - bladder - urinary incontinence - myelomeningocele

Publikationsverlauf

Eingereicht: 29. Januar 2022

Angenommen: 06. Oktober 2022

Artikel online veröffentlicht:
28. Dezember 2022

• Referencias

• 1 Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164 (3 Pt 1): 692-697
• 2 Blok B. (Chair), D. Castro-Diaz, G. Del Popolo, et al. (2020). EAU Guidelines on Neurourology. Accessed June 6, 2021. https://uroweb.org/guideline/neuro-urology
• 3 Radmayr C, Bogaert G, Dogan HS. et al. (2021). EAU/ESPU Paediatric Urology Guidelines. Accessed June 6, 2021. https://uroweb.org/guideline/paediatric-urology
• 4 Leitner L, Guggenbühl-Roy S, Knüpfer SC. et al. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned. Eur Urol 2016; 70 (03) 522-528
• 5 Greer T, Abbott J, Breytenbach W. et al. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. J Pediatr Urol 2016; 12 (02) 94.e1-94.e6
• 6 Sager C, Burek C, Bortagaray J. et al. Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder. Pediatr Surg Int 2014; 30 (01) 79-85
• 7 Austin PF, Franco I, Dobremez E, Kroll P, Titanji W, Geib T, Jenkins B, Hoebeke PB. OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children. Neurourol Urodyn 2021 Jan;40(1):493-501. doi: 10.1002/nau.24588. Epub 2020 Dec 11. PMID: 33305474; PMCID: PMC7839517.
• 8 Austin PF, Bauer SB, Bower W. et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn 2016; 35 (04) 471-481
• 9 Fortin A, Morin V, Ramsay S, Gervais P, Bolduc S. Adherence to antimuscarinics in children with overactive bladder. Paediatr Child Health 2017; 22 (05) 255-258
• 10 Nadeau G, Schröder A, Moore K. et al. Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. Can Urol Assoc J 2014; 8 (5-6): 175-180
• 11 Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003; 44 (02) 165-174
• 12 Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49 (04) 644-650
• 13 Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002; 59 (03) 325-327 , discussion 327–328
• 14 Hascoet J, Manunta A, Brochard C. et al; French Referral Network of Spina Bifida. Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review. Neurourol Urodyn 2017; 36 (03) 557-564
• 15 Riccabona M, Koen M, Schindler M. et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004;171(2 Pt 1):845–848, discussion 848
• 16 Figueroa V, Romao R, Pippi Salle JL. et al. Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol 2014; 10 (02) 368-373
• 17 Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 2006; 175 (3 Pt 1): 1102-1105
• 18 Hascoet J, Peyronnet B, Forin V. et al. Intra-detrusor injections of botulinum toxin type a in children with spina bifida: A multicenter study. Urology 2018; 116: 161-167